Cargando…
The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300514/ https://www.ncbi.nlm.nih.gov/pubmed/37172207 http://dx.doi.org/10.2337/dc23-0129 |
| _version_ | 1785064604579135488 |
|---|---|
| author | Sridhar, Vikas S. Heerspink, Hiddo J.L. Davies, Michael J. Banks, Phillip Girard, Manon Garg, Satish K. Cherney, David Z.I. |
| author_facet | Sridhar, Vikas S. Heerspink, Hiddo J.L. Davies, Michael J. Banks, Phillip Girard, Manon Garg, Satish K. Cherney, David Z.I. |
| author_sort | Sridhar, Vikas S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10300514 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103005142023-06-29 The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3 Sridhar, Vikas S. Heerspink, Hiddo J.L. Davies, Michael J. Banks, Phillip Girard, Manon Garg, Satish K. Cherney, David Z.I. Diabetes Care e-Letter – Observations American Diabetes Association 2023-07 2023-05-12 /pmc/articles/PMC10300514/ /pubmed/37172207 http://dx.doi.org/10.2337/dc23-0129 Text en © 2023 by the American Diabetes Association https://www.diabetesjournals.org/journals/pages/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license. |
| spellingShingle | e-Letter – Observations Sridhar, Vikas S. Heerspink, Hiddo J.L. Davies, Michael J. Banks, Phillip Girard, Manon Garg, Satish K. Cherney, David Z.I. The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3 |
| title | The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3 |
| title_full | The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3 |
| title_fullStr | The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3 |
| title_full_unstemmed | The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3 |
| title_short | The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3 |
| title_sort | effects of sotagliflozin in type 1 diabetes on clinical markers associated with cardiorenal protection: an exploratory analysis of intandem3 |
| topic | e-Letter – Observations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300514/ https://www.ncbi.nlm.nih.gov/pubmed/37172207 http://dx.doi.org/10.2337/dc23-0129 |
| work_keys_str_mv | AT sridharvikass theeffectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT heerspinkhiddojl theeffectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT daviesmichaelj theeffectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT banksphillip theeffectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT girardmanon theeffectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT gargsatishk theeffectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT cherneydavidzi theeffectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT sridharvikass effectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT heerspinkhiddojl effectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT daviesmichaelj effectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT banksphillip effectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT girardmanon effectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT gargsatishk effectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 AT cherneydavidzi effectsofsotagliflozinintype1diabetesonclinicalmarkersassociatedwithcardiorenalprotectionanexploratoryanalysisofintandem3 |